Key result
VERVE-102 is a next-generation PCSK9 base-editing therapy developed for durable LDL-cholesterol reduction to combat atherosclerotic cardiovascular disease.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
LDL-cholesterol is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of morbidity and mortality worldwide. PCSK9, the third gene implicated in familial h...
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question. VERVE-102 is a next-generation PCSK9 base-editing therapy developed for durable LDL-cholesterol reduction to combat atherosclerotic cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: